Iptacopan

• Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting
  2023-509331-83-00 Phase III 7 countries Novartis Pharma AG
• A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatm… Recruiting
  2023-504550-35-00 Phase III 4 countries Novartis Pharma AG
• Evaluate long-term safety, tolerability and efficacy of iptacopan in study participants with aHUS Recruiting
  2022-502965-34-00 Phase III 1 country Novartis Pharma AG
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients w… Recruiting
  2023-507064-39-00 Phase III 9 countries Novartis Pharma AG
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 Phase III 10 countries Novartis Pharma AG
• Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting
  2023-509332-26-00 Phase II 5 countries Novartis Pharma AG
• Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting
  2023-509343-27-00 Phase III/IV 7 countries Novartis Pharma AG
• A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended
  2023-510525-15-00 Phase II 9 countries Novartis Pharma AG
• Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended
  2023-509843-28-00 Phase III 7 countries Novartis Pharma AG
• A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended
  2023-508690-92-00 Phase III/IV 13 countries Novartis Pharma AG
• A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb… Ended
  2022-502148-10-00 Phase III 4 countries Novartis Pharma AG
• Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapy Ended
  2023-508840-22-00 Phase III 5 countries Novartis Pharma AG
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 Phase III 12 countries Novartis Pharma AG

Showing 1–13 of 13 trials